The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome
Open accessAbstract
Background: More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric infection. Methods: Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the Irritable Bowel Syndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability. Results: Fifty-four glutamine and 52 placebo subjects completed the 8-week study. The primary endpoint occurred in 43 (79.6%) in the glutamine group and 3 (5.8%) in the placebo group (a 14-fold difference). Glutamine also reduced all secondary endpoint means: IBS-SS score at 8 weeks (301 vs 181, p<0.0001), daily bowel movement frequency (5.4 vs 2.9±1.0, p<0.0001), Bristol Stool Scale (6.5 vs 3.9, p<0.0001) and intestinal permeability (0.11 vs 0.05; p<0.0001). ‘Intestinal hyperpermeability’ (elevated urinary lactulose/mannitol ratios) was normalised in the glutamine but not the control group. Adverse events and rates of study-drug discontinuation were low and similar in the two groups. No serious adverse events were observed. Conclusions: In patients with IBS-D with intestinal hyperpermeability following an enteric infection, oral dietary glutamine supplements dramatically and safely reduced all major IBS-related endpoints. Large randomised clinical trials (RCTs) should now be done to validate these findings, assess quality of life benefits and explore pharmacological mechanisms. Trial registration number: NCT1414244 ; Results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, a meta-analysis reported that modest increases in zinc intake (9.2-25 mg/day) over longer durations (≥12 weeks) were associated with improvements in insulin resistance, fasting glycemia, LDL-c, total cholesterol, and triglycerides, both in healthy and metabolically impaired populations [181].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [181]
In the citing paper
“Zinc also plays a role in lipid metabolism through antioxidant, anti-inflammatory, and other mechanisms that may modulate atherosclerosis and cardiovascular disease (CVD) risk [181].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Burden of Gastrointestinal Disease in the United States: 2012 Update
Peery, A. F., Dellon, E. S., Lund, J. L., Crockett, S. D., McGowan, C., Bulsiewicz, W. J., Gangarosa, L. M., Thiny, M. T., Stizenberg, K., Morgan, D. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.08.002 · Cited by 2,010
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
Reciprocal interactions of the intestinal microbiota and immune system
Maynard, C. L., Elson, C. O., Hatton, R. D., & Weaver, C. T. (2012) · Nature · doi:10.1038/nature11551 · Cited by 1,598
Spiller, R. C., Jenkins, D., Thornley, J. P., Hebden, J. M., Wright, T., Skinner, M., & Neal, K. R. (2000) · Gut · doi:10.1136/gut.47.6.804 · Cited by 1,155
Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M. D., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 1,102
Immunity, Inflammation, and Allergy in the Gut
MacDonald, T. T., & Monteleone, G. (2005) · Science · doi:10.1126/science.1106442 · Cited by 1,051
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Cited by
Sorted by citations
Leaky gut: mechanisms, measurement and clinical implications in humans
Camilleri, M. (2019) · Gut · doi:10.1136/gutjnl-2019-318427 · Cited by 1,081
Regulation of the intestinal barrier by nutrients: The role of tight junctions
Suzuki, T. (2020) · Animal Science Journal · doi:10.1111/asj.13357 · Cited by 796
Global burden of irritable bowel syndrome: trends, predictions and risk factors
Black, C. J., & Ford, A. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0286-8 · Cited by 666
Gut barrier disruption and chronic disease
Martel, J., Chang, S.-H., Ko, Y.-F., Hwang, T.-L., Young, J. D., & Ojcius, D. M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.01.002 · Cited by 514
Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier
Barbara, G., Barbaro, M. R., Fuschi, D., Palombo, M., Falangone, F., Cremon, C., Marasco, G., & Stanghellini, V. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.718356 · Cited by 446
Metadata
- Authors
- Zhou, Q., Verne, M. L., Fields, J. Z., Lefante, J. J., Basra, S., Salameh, H., & Verne, G. N.
- Affiliations
- Tulane University (US)
- Texas A&M Health Science Center (US)
- The University of Texas Medical Branch at Galveston (US)
- Corresponding author
- Verne, G Nicholas
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2018-08-14
- Volume
- 68
- Issue
- 6
- Pages
- 996-1002
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC9549483
- OpenAlex
- W2888929155
- Cited by
- 195
- References
- 40
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 26 · 2023: 22 · 2022: 21 · 2021: 26 · 2020: 31 · 2019: 13 · 2018: 5
- FWCI
- 17.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Institute of General Medical Sciences
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Complementary and Integrative Health
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- dietary glutamine, post-infectious irritable bowel syndrome, diarrhoea-predominant IBS, intestinal permeability, leaky gut, gastrointestinal infections, lactulose/mannitol ratio, IBS symptom severity, stool frequency, stool consistency, oral supplementation
- MeSH terms
- Administration, Oral, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Enteritis, Female, Glutamine, Humans, Intestinal Mucosa, Male, Reference Values, Severity of Illness Index, Treatment Outcome, Risk Assessment, Dietary Supplements, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
